Tab. SIII.
Estimated incidence (new cases/100,000 residents) of cancers attributable to infectious agents in Southern Italy regions in 2018.
| Gender | Abruzzo | Basilicata | Calabria | Campania | Molise | Puglia | Sardegna | Sicilia | All Southern regions | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Resident population as to January 2018 | M | 641,185 | 278,882 | 959,437 | 2,841,049 | 152,228 | 1,967,751 | 810,072 | 2,445,343 | 10,095,947 | |
| F | 674,011 | 288,236 | 997,250 | 2,985,811 | 156,265 | 838,104 | 2,581,646 | 10,601,814 | |||
| M+F | 1,315,196 | 567,118 | 1,956,687 | 5,826,860 | 308,493 | 4,048,242 | 1,648,176 | 5,026,929 | 20,697,761 | ||
| Population covered by Cancer Registries (%) | M+F | 0 | 100 | 64 | 71 | 0 | 54 | 42 | 91 | 65 | |
|
Cancer site
(ICD-10) |
Infectious agent | ||||||||||
| Non-cardia stomach (C16.1-C16.9) | Hp | M | 20.0 | 30.0 | 24.4 | 19.9 | 20.5 | 17.6 | 17.8 | 16.1 | 20.8 |
| F | 13.1 | 17.9 | 12.5 | 12.8 | 13.7 | 11.9 | 11.8 | 10.2 | 13.0 | ||
| M+F | 33.1 | 47.9 | 36.9 | 32.7 | 34.2 | 29.5 | 29.6 | 26.3 | 33.8 | ||
| MALT (C88.4) | Hp | M | 04 | 0.00 | 0.2 | 0.3 | 0.5 | 0.5 | 0.7 | 0.3 | 0.4 |
| F | 0.2 | 0.5 | 0.4 | 0.2 | 0.0 | 0.3 | 0.4 | 0.2 | 0.3 | ||
| M+F | 0.6 | 0.5 | 0.6 | 0.5 | 0.5 | 0.8 | 1.1 | 0.5 | 0.7 | ||
| Total Hp-associated cancers | Hp | M | 20.3 | 30.0 | 24.6 | 20.2 | 21.0 | 18.1 | 18.5 | 16.4≤ | 21.1 |
| F | 13.3 | 18.4 | 12.9 | 13.0 | 13.7 | 12.1 | 12.1 | 10.3 | 13.2 | ||
| M+F | 33.6 | 48.4 | 37.5 | 33.2 | 34.7 | 30.2 | 30.6 | 26.7 | 34.3 | ||
| Liver (C22) | HBV (± HDV) + HCV | M | 20.8 | 21.5 | 20.4 | 22.2 | 21.0 | 19.4 | 22.5 | 14.3 | 20.3 |
| F | 10.7 | 9.9 | 10.1 | 10.8 | 11.3 | 9.2 | 10.7 | 7.5 | 10.0 | ||
| M+F | 31.5 | 31.4 | 30.5 | 33.0 | 32.3 | 28.6 | 33.2 | 21.8 | 30.3 | ||
| Uterine cervix (C53) | HPV | M | - | - | - | - | - | - | - | - | - |
| F | 7.1 | 8.0 | 7.4 | 6.8 | 7.0 | 6.9 | 7.0 | 6.9 | 7.1 | ||
| M+F | 7.1 | 7.98 | 7.42 | 6.80 | 7.04 | 6.87 | 7.04 | 6.86 | 7.14 | ||
| Vulva (C51) | HPV | M | - | - | - | - | - | - | - | - | - |
| F | 1.0 | 0.9 | 1.1 | 0.9 | 1.1 | 1.1 | 0.8 | 0.9 | 1.0 | ||
| M+F | 1.0 | 0.9 | 1.1 | 0.9 | 1.1 | 1.1 | 0.8 | 0.9 | 1.0 | ||
| Vagina (C52) | HPV | M | - | - | - | - | - | - | - | - | |
| F | 0.5 | 0.3 | 0.2 | 0.5 | 0.5 | 0.5 | 0.4 | 0.3 | 0.4 | ||
| M+F | 0.5 | 0.3 | 0.2 | 0.5 | 0.5 | 0.5 | 0.4 | 0.3 | 0.4 | ||
| Penis (C60) | HPV | M | 1.2 | 0.7 | 1.2 | 1.0 | 1.3 | 1.0 | 1.0 | 1.1 | 1.1 |
| F | - | - | - | - | - | - | - | - | - | ||
| M+F | 1.2 | 0.7 | 1.2 | 1.0 | 1.3 | 1.0 | 1.0 | 1.1 | 1.1 | ||
| Oral cavity (C00-C08) | HPV | M | 0.4 | 0.5 | 0.3 | 0.3 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 |
| F | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | ||
| M+F | 0.6 | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | ||
| Oropharynx
(C09-C10. C12-C14) |
HPV | M | 0.8 | 1.3 | 0.4 | 0.8 | 0.8 | 0.8 | 1.8 | 0.6 | 0.9 |
| F | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | ||
| M+F | 1.00 | 1.4 | 0.6 | 1.0 | 1.0 | 1.0 | 2.0 | 0.8 | 1.01 | ||
| Larynx (C32) | HPV | M | 0.8 | 0.5 | 0.7 | 0.8 | 0.8 | 0.6 | 0.8 | 0.6 | 0.7 |
| F | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | ||
| M+F | 0.9 | 0.5 | 0.8 | 0.9 | 0.9 | 0.7 | 0.9 | 0.7 | 0.8 | ||
| Total HPV-associated cancers | HPV | M | 3.2 | 3.0 | 2.6 | 2.9 | 3.3 | 2.8 | 4.1 | 2.6 | 3.0 |
| F | 9.0 | 9.3 | 9.1 | 8.6 | 9.1 | 8.9 | 8.7 | 8.4 | 8.9 | ||
| M+F | 12.2 | 12.3 | 11.7 | 11.5 | 12.4 | 11.7 | 12.8 | 11.0 | 11.9 | ||
| Nasopharynx (C11) | EBV (HHV4) | M | 1.6 | 2.3 | 1.5 | 1.2 | 1.6 | 1.3 | 1.2 | 2.0 | 1.6 |
| F | 0.5 | 0.6 | 0.2 | 0.4 | 0.5 | 0.4 | 0.3 | 0.6 | 0.4 | ||
| M+F | 2.1 | 2.9 | 1.7 | 1.6 | 2.1 | 1.7 | 1.5 | 2.6 | 2.0 | ||
| Burkitt’s lymphoma
(C83.7) |
EBV (HHV4) ± Pf | M | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 |
| F | 0.00 | 0.0 | 0.00 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| M+F | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | ||
| Hodgkin’s lymphoma (C81) | EBV (HHV4) | M | 1.4 | 1.0 | 1.4 | 1.5 | 1.4 | 1.3 | 1.6 | 1.5 | 1.4 |
| F | 1.1 | 1.6 | 1.6 | 1.2 | 1.2 | 1.3 | 1.3 | 1.0 | 1.3 | ||
| M+F | 2.5 | 2.6 | 3.0 | 2.7 | 2.6 | 2.6 | 2.9 | 2.5 | 2.7 | ||
| Total EBV-associated cancers | EBV | M | 3.1 | 3.4 | 3.0 | 2.7 | 3.0 | 2.8 | 2.9 | 3.5 | 3.0 |
| F | 1.5 | 2.2 | 1.8 | 1.6 | 1.7 | 1.7 | 1.6 | 1.6 | 1.7 | ||
| M+F | 4.6 | 5.6 | 4.8 | 4.3 | 4.7 | 4.5 | 4.5 | 5.1 | 4.7 | ||
| Kaposi’s sarcoma
(C46) |
KSHV (HHV8) | M | 3.0 | 3.6 | 3.0 | 2.4 | 2.6 | 4.3 | 3.2 | 2.0 | 3.0 |
| F | 1.3 | 1.0 | 0.8 | 1.1 | 1.3 | 2.2 | 1.4 | 0.7 | 1.2 | ||
| M+F | 4.3 | 4.6 | 3.8 | 3.5 | 3.9 | 6.4 | 4.6 | 2.7 | 4.2 | ||
| Adult T cell lymphoma/leukemia (C91.5) | HTLV1 | M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
| F | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| M+F | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | ||
| All the above cancers | M | 50.3 | 61.4 | 53.5 | 50.3 | 50.8 | 47.4 | 51.4 | 38.8 | 50.5 | |
| F | 35.9 | 40.9 | 34.6 | 35.0 | 37.0 | 34.0 | 34.6 | 28.5 | 35.1 | ||
| M+F | 86.2 | 102.3 | 88.1 | 85.4 | 87.8 | 81.4 | 86.0 | 67.3 | 85.6 |
Hp: Helicobacter pylori; HBV: hepatitis B virus; HCV: hepatitis C virus; HDV: hepatitis D virus (Delta agent); HPV: human papillomavirus; EBV: Epstein-Barr virus; HHV4: human herpesvirus 4; Pf: Plasmodium falciparum; KSKV: Kaposi’s sarcoma virus; HHV8: human herpesvirus 8; HTLV: human T-lymphotropic virus; M: males; F: females.